drugset / Trial / NCT00633724
Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer
Phase 1
Completed
9 enrolled
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, immune response and clinical response of different doses of HLA-A\*2402 restricted epitope peptides URLC10, TTK, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.
Timeline
- Start
- 2007-05
- Primary completion
- 2012-06
- Completion
- 2012-06
Publications
- Background Suda T, Tsunoda T, Uchida N, Watanabe T, Hasegawa S, Satoh S, Ohgi S, Furukawa Y, Nakamura Y, Tahara H. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006 May;97(5):411-9. doi: 10.1111/j.1349-7006.2006.00194.x.
- Background Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15;10(24):8577-86. doi: 10.1158/1078-0432.CCR-04-0104.
- Background Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9. doi: 10.1158/1078-0432.CCR-06-0750.
- Background Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46. doi: 10.1158/0008-5472.CAN-04-3759.
- Background Watanabe T, Suda T, Tsunoda T, Uchida N, Ura K, Kato T, Hasegawa S, Satoh S, Ohgi S, Tahara H, Furukawa Y, Nakamura Y. Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. Cancer Sci. 2005 Aug;96(8):498-506. doi: 10.1111/j.1349-7006.2005.00073.x.
- Suzuki H, Fukuhara M, Yamaura T, Mutoh S, Okabe N, Yaginuma H, Hasegawa T, Yonechi A, Osugi J, Hoshino M, Kimura T, Higuchi M, Shio Y, Ise K, Takeda K, Gotoh M. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med. 2013 Apr 11;11:97. doi: 10.1186/1479-5876-11-97.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CDCA1 | Unknown | 0.5 mg | Subcutaneous |
| Subject | CDCA1 | Unknown | 1 mg | Subcutaneous |
| Subject | CDCA1 | Unknown | 3 mg | Subcutaneous |
| Subject | URLC10 | Peptide | 0.5 mg | Subcutaneous |
| Subject | URLC10 | Peptide | 1 mg | Subcutaneous |
| Subject | URLC10 | Peptide | 3 mg | Subcutaneous |
| Subject | VEGFR1 | Peptide | 0.5 mg | Subcutaneous |
| Subject | VEGFR1 | Peptide | 1 mg | Subcutaneous |
| Subject | VEGFR1 | Peptide | 3 mg | Subcutaneous |
| Subject | VEGFR2 | Peptide | 0.5 mg | Subcutaneous |
| Subject | VEGFR2 | Peptide | 1 mg | Subcutaneous |
| Subject | VEGFR2 | Peptide | 3 mg | Subcutaneous |